Apellis Pharmaceuticals Inc.

NAS: APLS

GO
/marketstate/country/us

After Hours

/zigman2/quotes/202103251/composite

$

39.67

Change

0.00 0.00%

Volume

Volume 5,153

Jan 25, 2022, 4:44 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/202103251/composite

Previous close

$ 38.78

$ 39.67

Change

+0.89 +2.29%

Day low

Day high

$37.15

$40.06

Open
Open: 38.34

52 week low

52 week high

$27.50

$73.00

Open

Market cap

$3.72B

Average volume

1.08M

P/E ratio

N/A

Rev. per Employee

$685,222

EPS

-6.49

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/apls

MarketWatch News on APLS

  1. 4 Midsize Biotech Stocks That Have Breakout Potential

    9:02 a.m. Sept. 23, 2021

    - Barron's Online

  2. Apellis Stock Plunges After Its Eye Treatment Gets Mixed Results

    12:02 p.m. Sept. 10, 2021

    - Barron's Online

  3. Apellis Pharmaceuticals downgraded to neutral from outperform at Wedbush

    6:20 a.m. Sept. 10, 2021

    - Tomi Kilgore

  4. Apellis stock price target cut to $57 from $101 at J.P. Morgan

    5:58 a.m. Sept. 10, 2021

    - Tomi Kilgore

  5. Apellis Pharmaceuticals upgraded to outperform from neutral at Wedbush

    6:18 a.m. Aug. 19, 2021

    - Tomi Kilgore

  6. Apellis Pharmaceuticals price target raised to $104 from $78, stock rated strong buy

    7:49 a.m. Jan. 8, 2021

    - Tonya Garcia

  7. Apellis stock price target raised to $87 from $50 at J.P. Morgan

    7:03 a.m. Dec. 4, 2020

    - Tomi Kilgore

  8. Apellis Pharmaceuticals started at buy with $40 stock price target at Stifel Nicolaus

    6:34 a.m. Sept. 1, 2020

    - Tomi Kilgore

  9. 21 Risky Stocks That Might Have Borrowed Too Much

    10:47 a.m. May 19, 2020

    - Barron's Online

  10. Apellis Pharmaceuticals started at strong buy with $86 stock price target at Raymond James

    6:41 a.m. April 1, 2020

    - Tomi Kilgore

  11. Apellis Pharmaceuticals upgraded to neutral from underperform at Wedbush

    6:47 a.m. March 11, 2020

    - Tomi Kilgore

  12. Apellis Pharmaceuticals stock price target raised to $62 from $52 at Oppenheimer

    7:14 a.m. Jan. 8, 2020

    - Tomi Kilgore

  13. Apellis Stock Soars After Head-to-Head Drug Trial Vs Alexion

    10:30 a.m. Jan. 7, 2020

    - Barron's Online

  14. Apellis Pharmaceuticals upgraded to overweight from neutral at J.P. Morgan

    5:56 a.m. July 12, 2019

    - Tomi Kilgore

  15. Apellis Pharmaceuticals started at outperform with $52 stock price target at Oppenheimer

    7:17 a.m. July 9, 2019

    - Tomi Kilgore

  16. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/apls

Other News on APLS

  1. Tracking Baker Brothers Portfolio - Q3 2021 Update

    10:32 p.m. Jan. 4, 2022

    - Seeking Alpha

  2. Apellis Pharma announces $300M common stock offering

    4:24 p.m. Nov. 15, 2021

    - Seeking Alpha

  3. Loading more headlines...
/news/pressrelease/company/us/apls

Press Releases on APLS

  1. Loading more headlines...

Rates »

Trending Tickers
  • /zigman2/quotes/202561856/composite MSTR-17.84%
  • /zigman2/quotes/205315244/composite DHT-4.09%
X
Powered by StockTwits
Link to MarketWatch's Slice.